Daiichi, Sankyo Deal Will Fend Off Foreign Competition In Japan, Build In U.S.
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Daiichi/Sankyo merger will build domestic position, broaden U.S. market penetration. Daiichi Sankyo will be the second largest Japanese pharmaceutical company based on domestic sales. Combined global sales force is 2,200 reps, with plans to expand. U.S. sales force is 850 reps. Integration should be complete by April 2007